Jeffrey A. Cohen
 | This biographical article is written like a résumé. (April 2019) |
Jeffrey A. Cohen | |
|---|---|
| Born | October 14, 1954 |
| Scientific career | |
| Institutions | Cleveland Clinic (Staff Neurologist) |
Jeffrey Alan Cohen (born October 14, 1954) is an American neurologist specializing in multiple sclerosis and Director of Experimental Neurotherapeutics at the Cleveland Clinic Mellen Center for Multiple Sclerosis.
Education[edit]
 | This section of a biography of a living person does not include any references or sources. (April 2019) |
B.A. - Connecticut College, New London, Connecticut M.D. - University of Chicago Pritzker School of Medicine Chicago, Illinois Postdoctoral training - Neurology - University of Pennsylvania
Notable contributions[edit]
- Global Principal Investigator of the ACT (Avonex Combination Trial) clinical trial[1]
- Global Principal Investigator of the TRANSFORMS Phase III trial of Fingolimod, a novel oral agent for use in treating Multiple Sclerosis, the primary results of which were presented at the American Academy of Neurology Annual Meeting in May 2009.[2]
- Global Principal Investigator of the IMPACT trial, the first study to use the MS Functional Composite as the primary outcome measure in a clinical trial.[3]
- Co-Editor of the textbook "Multiple Sclerosis Therapeutics", ISBN 1841845256[4]
- Fellowship Director of the Mellen Center for MS National Multiple Sclerosis Society-supported Fellowship
References[edit]
- ^ "ACT primary results manuscript".
- ^ "Oral Fingolimod Superior to Interferon Beta1-a in RRMS". Medscape.
- ^ "IMPACT primary results manuscript".
- ^ Minkoff, Eli; Baker, Eli (March 6, 2007). Multiple Sclerosis Therapeutics. CRC Press. ISBN 9780203012055 – via Google Books.
External links[edit]
| International | |
|---|---|
| National | |
| Other | |
   | This biographical article related to a physician in the United States is a stub. You can help Wikipedia by expanding it. |